Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAXI: Thymoglobulin vs Daclizumab in High-Risk Renal Transplant
NCT00682292Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- May 2001
- Primary completion
- Nov 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of antithymocyte globulin, daclizumab in renal allograft rejection, sponsored by CHU de Lille. Started May 2001; status: completed.
02
Drugs
antithymocyte globulindaclizumab
03
Conditions
renal allograft rejection
Beyond the preview
Go deeper on NCT00682292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00682292.